William Blair initiates coverage of Vertex at 'outperform'
An analyst from William Blair initiated coverage of Vertex (NASDAQ: VRTX) at 'outperform' . Prior to this rating, Vertex had 20 buy ratings, 11 hold ratings, and 0 sell ratings. For...
-
-
6 big analyst picks & cuts: RingCentral stock jumps on upgrade & merger talks
By Davit KirakosyanHere is your Pro Recap of the biggest analyst picks and cuts you may have missed since Friday: upgrades at |RingCentral, Dollar General, UWM, and Hamilton Lane; downgrades...
-
TCS partners Google Cloud to launch next-gen generative AI offering
New Delhi, May 22 (IANS) Tata Consultancy Services (NS:TCS) on Monday announced an expanded partnership with Google (NASDAQ:GOOGL) Cloud, with launching 'TCS Generative AI' which leverages...
-
Pro Exclusive: 5 cash cows to plump your portfolio
Here is your VIP list of Pro Picks for the week, offered exclusively to InvestingPro subscribers: a hand-picked selection of S&P 500 stocks that InvestingPro awarded a high financial...
-
Oppenheimer maintains Vertex at 'outperform' with a price target of $410.00
An analyst from Oppenheimer maintained Vertex (NASDAQ: VRTX) at '' 'outperform' and a price target of $410.00. Prior to this rating, Vertex had 20 buy ratings, 10 hold ratings, and 0 sell...
-
Vertex Pharma Announces FDA Approval of KALYDECO
Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO® (ivacaftor) for use in children with...
-
Piper Sandler new coverage Vertex Overweight, PT $385.00
A Piper Sandler analyst initiated new coverage Vertex (NASDAQ: VRTX) Overweight rating and a price target of $385.00. Prior to this rating, Vertex had 19 buy ratings, 10 hold ratings, and...
-
Bernstein maintains Vertex at Outperform, PT $363.00
A Bernstein analyst maintained Vertex (NASDAQ: VRTX) at Outperform and a price target of $363.00 from a prior price target of %currency%%price%. Prior to this rating, Vertex had 19 buy...
-
Barclays maintains Vertex at Overweight, PT $384.00
A Barclays analyst maintained Vertex (NASDAQ: VRTX) at Overweight and a price target of $384.00 from a prior price target of %currency%%price%. Prior to this rating, Vertex had 19 buy...
-
ace turtle raises Rs 293 cr to expand retail footprint, tech stack
New Delhi, May 2 (IANS) Homegrown technology-native retail company ace turtle on Tuesday said it has raised $34 million (about Rs 293 crore) as part of its Series B funding.The company said...
-
Vertex earnings beat by $0.02, revenue topped estimates
Investing.com - Vertex (NASDAQ: VRTX) reported first quarter EPS of $3.05, $0.02 better than the analyst estimate of $3.03. Revenue for the quarter came in at $2.37B versus the consensus...
-
Vertex parties as AbbVie ends CF program
Vertex Pharmaceuticals (NASDAQ:VRTX) gained 5% Thursday after AbbVie Inc (NYSE:ABBV) announced the decision to discontinue its cystic fibrosis (CF) program. The news, according to...
-
Vertex Pharma Announces FDA Approval of TRIKAFTA
Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved the expanded use of TRIKAFTA®...
-
Vertex Pharma , CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion
Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the rolling Biologics License Applications (BLAs) to...
-
Essar project chosen to support UK's decarbonisation strategy
London, March 30 (IANS) Vertex (NASDAQ:VRTX) Hydrogen, a leading low carbon hydrogen production project, has been chosen by the UK government as part of one of the two hydrogen plants that...
-
Argus maintains Vertex at Buy
An Argus analyst maintained Vertex (NASDAQ: VRTX) at Buy and a price target of $350.00 from a prior price target of %currency%%price%. Prior to this rating, Vertex had 19 buy ratings, 10...
-
Vertex Pharma , CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that they have entered into a new non-exclusive licensing agreement...
-
Vertex Pharma Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin
Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (Nasdaq: VRTX) today announced publication in the New England Journal of Medicine (NEJM) of results from preclinical studies and a Phase 2...
-
Vertex Pharma Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes
(Updated - March 9, 2023 8:02 AM EST) Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the...
-
6 big upgrades: AGNC rises sharply on new buy rating | Pro Recap
By Davit Kirakosyan Investing.com -- In today's Pro Recap of the biggest upgrades since yesterday's session, AGNC climbed on a |JPMorgan Overweight rating, and Vertex was bumped up after...
-
Immunogen Enters License and Option Agreement with Vertex for Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents
ImmunoGen (NASDAQ:IMGN), Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs), today announced a global, multi-target license and option agreement...
-
Essar launches EET to invest $3.6 bn in energy transition in UK, India
London, Feb 27 (IANS) Essar Group, invested in Energy, Metals and Mining, Infrastructure and Technology sectors, has announced the formation of Essar Energy Transition (EET) to drive the...
-
Vertex Hydrogen signs agreements to supply over 1,000MW of hydrogen to decarbonise leading UK industries
New Delhi, Feb 23 (IANS) Vertex (NASDAQ:VRTX) Hydrogen is a leader in the energy transition, developing the UK's first large scale, low carbon hydrogen production hub at Essar's site in...
-
Vertex Pharma Tops Q4 EPS by 26c; Guides FY Revenue
Vertex Pharma (VRTX) reported Q4 EPS of $3.79, $0.26 better than the analyst estimate of $3.53. Revenue for the quarter came in at $2.3 billion versus the consensus estimate of $2.3...
-
Vertex earnings beat by $0.26, revenue was inline with estimates
Investing.com - Vertex (NASDAQ: VRTX) reported fourth quarter EPS of $3.79, $0.26 better than the analyst estimate of $3.53. Revenue for the quarter came in at $2.3B versus the consensus...
-
AI race, CVS M&A, Genesis recapitalization - what's moving markets
By Geoffrey Smith Investing.com -- The AI race heats up, with Alphabet and Baidu both nearing launches of tools to compete with Microsoft-backed ChatGPT. CVS is closing in on its second...
-
Vertex, Tata Chemicals Europe sign major low carbon hydrogen offtake agreement
New Delhi, Jan 26 (IANS) Vertex (NASDAQ:VRTX) Hydrogen has signed a 'Heads of Terms' offtake agreement for over 200 megawatts of low carbon hydrogen with Northwich-based Tata Chemicals...
-
Vertex Pharma financial projections 'significantly' raised at SVB Securities
By Sam Boughedda Vertex Pharma (NASDAQ:VRTX) was upgraded to Outperform from Market Perform by SVB Securities analysts who argue that the company's growth and durability are...
-
Vertex, Pilkington UK sign major low-carbon hydrogen supply agreement
Mumbai, Jan 4 (IANS) Vertex (NASDAQ:VRTX) Hydrogen has signed a ‘Heads of Terms offtake agreement for low-carbon hydrogen with Merseyside glass manufacturer Pilkington UK.St Helens'...
-
Dow, Nasdaq, and S&P 500 2022 winners and losers: energy, tech lead the way
By Daniel Shvartsman Investing.com -- Entering the last trading day of the year, it's no surprise to find the 2022 scoreboard filled with energy winners and tech losers.The Dow Jones...
-
Today's most important downgrades
By Davit Kirakosyan Oppenheimer downgraded Tesla (NASDAQ:TSLA) to Perform from Outperform, noting it believes increasing negative sentiment on Twitter could linger long term, limiting its...
-
Vertex, Encirc sign major low carbon hydrogen supply agreement to deliver Net Zero glass
New Delhi, Dec 14 (IANS) Vertex (NASDAQ:VRTX) Hydrogen has announced the signing of a 'Heads of Terms' offtake agreement for 300plus megawatts of low carbon hydrogen with Encirc.Encirc,...
-
Essar Oil UK to build carbon capture facility
London, Nov 30 (IANS) Essar Oil UK Limited has announced its plan to build a 360 million-pound major new carbon capture plant at its Stanlow refinery in line with its ambition to become a...
-
Vertex earnings, Revenue beat in Q3
Investing.com - Vertex (NASDAQ:VRTX) reported on Wednesday third quarter {{erl-1163495||earnings that beat analysts' forecasts and revenue that topped expectations. Vertex announced...
-
Vertex Energy earnings beat, Revenue misses in Q3
Investing.com - Vertex (NASDAQ:VRTX) Energy reported on Tuesday third quarter {{erl-40103||earnings that beat analysts' forecasts and revenue that fell short of expectations. Vertex Energy...
-
Vertex earnings, Revenue beat in Q3
Investing.com - Vertex (NASDAQ:VRTX) reported on Thursday third quarter {{erl-6353||earnings that beat analysts' forecasts and revenue that topped expectations. Vertex announced earnings...
-
Dow Futures Trade Lower, Amazon Tanks 12.7% After Earnings
By Oliver Gray Investing.com - U.S. stock futures fell during Thursday’s evening trade, after major benchmark indices finished the regular session mixed as investors digested a slew of...
-
Vertex Pharma Tops Q3 EPS by 39c; Raises Revenue Outlook
Vertex Pharma (VRTX) reported Q3 EPS of $4.01, $0.39 better than the analyst estimate of $3.62. Revenue for the quarter came in at $2.33 billion versus the consensus estimate of $2.22...
-
After-Hours Movers: Amazon Sinks on Lower Guidance, Pinterest Up on Beat
After-Hours Stock Movers: Amazon.com (NASDAQ:AMZN) 14% LOWER; {{erl-6435||reported Q3 EPS of $0.28, $0.06 better than the analyst estimate of $0.22. Revenue for the quarter came in at $127.1...
-
Essar Oil UK signs offtake agreement with Vertex Hydrogen
London, Sep 28 (IANS) Essar Oil UK Limited (Essar) has announced that it has signed a ‘Heads of Terms offtake agreement with Vertex (NASDAQ:VRTX) Hydrogen (Vertex) for the supply of 280MW...
-
Digital banking infrastructure provider Signzy raises Rs 210 cr
Bengaluru, Sep 26 (IANS) Digital banking infrastructure provider Signzy on Monday said it has raised Rs 210 crore (about $26 million) from Gaja Capital and its existing investors, Vertex...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
